Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.

Molecular oncology - 1 Sept 2020

Chen Yu, Li Yi, Guan Yanfang, Huang Yingying, Lin Jing, Chen Lizhu, Li Jin, Chen Gang, Pan Leong Kin, Xia Xuefeng, Xu Ning, Chang Lianpeng, Guo Zengqing, Pan Jianji, Yi Xin, Chen Chuanben

Abstract excerpt

Predictive biomarkers of response to immune checkpoint inhibitors (ICI) help to identify cancer patients who will benefit from immunotherapy. Protein kinase, DNA-activated, catalytic subunit (PRKDC) is an important gene for DNA double-strand break (DSB) repair and central T-cell tolerance. We aimed to investigate the association between PRKDC mutations and tumor mutation burden (TMB), tumor microenvironment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to DNA-Activated Protein Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Killer Cells, Natural

Share to Lymphocytes, Tumor-Infiltrating

Share to Multivariate Analysis

Share to T-Lymphocytes, Cytotoxic

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 32502294
DOI: 10.1002/1878-0261.12739
PMCID: PMC7463346

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.PMID 32502294Read ↗

Potential Value of PRKDC as a Therapeutic Target and Prognostic Biomarker in Pan-CancerSemantic proximity Read ↗

TMBpred: A bioinformatics tool for precise prediction of the Tumor Mutation Burden in 14 cancer typesSemantic proximity Read ↗

CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment.Semantic proximity Read ↗

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.Semantic proximity Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

PRKDC : new biomarker and drug target for checkpoint blockade immunotherapySemantic proximity Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.Semantic proximity Read ↗

CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors.Semantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Predictive Value of KDM5C Alterations for Immune Checkpoint Inhibitors Treatment Outcomes in Patients With Cancer.Semantic proximity Read ↗

Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor typesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.